Market Access Impact: Multiple Sclerosis (US) 2017
|市場進入的課題:多發性硬化症 (美國) Market Access Impact: Multiple Sclerosis (US) 2017|
|出版日期: 2017年07月01日||內容資訊: 英文||
New products suffer from market access barriers, as established therapies reap the spoils
Despite prescribing rates for many of the leading treatments for multiple sclerosis in the US being healthy, market barriers affect nearly 1 in 5 prescriptions. This isn't all bad news for some brands, but others are losing out on market share gains. One of the new kids on the block could get a market share bump of over 100% if neurologists could prescribe it instead of its competitors.
Market Access Impact: Multiple Sclerosis (US) shows you how 7 barriers affect your market share, revealing how much you win and lose, who you take share from, and who gets your lost share.
Based on a survey of 100 US-based neurologists, the report covers 12 major therapies from Genzyme, Biogen, Bayer, Teva, Sanofi, Novartis, Roche, EMD Serono, and AbbVie/Biogen.
Not your market? Click here to see the EU5 report
Insight into 12 Major Asthma/COPD Drugs
Exploring Market Access Barriers
Market Access Impact: Multiple Sclerosis (US) explores key issues affecting drug manufacturers. You'll learn:
How barriers affect market access:
How barriers affect your brand:
A Report Based on Expert Knowledge
We surveyed 100 US-based neurologists, chosen from the largest community of validated physicians in the world.
All respondents have:
We conducted the survey between July 3rd and 13th, 2017.
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.